Search Results
Search
Filter by
Content Type
Client
Focus Area
Capability
Topic
-
Improving Blood Transfusion Safety and Clinical Practices
November 4, 2025
Every 2 seconds, someone in the U.S. needs blood, platelets, or both. This translates to 16 million blood components transfused in patients annually. But how…
-
Holly Sawyer
Senior Research Associate
-
Novel Strategies Transform Clinical Trials Into Future Opportunities
October 1, 2025
For the rigorous evaluation of novel medicines, clinical trials are essential to ensure safety and efficacy. However, clinical trials are experiencing turbulent times due to…
-
Real-World Insights: Nirsevimab’s Protection Against RSV in Infants
September 17, 2025
Each year in the U.S., respiratory syncytial virus, commonly known as RSV, leads to approximately 58,000 to 80,000 hospitalizations among children under age 5. The…
-
Mannshardt Joins NC State Advisory Board for New Data Science Graduate Program
September 10, 2025
Liz Mannshardt, PhD, Westat’s Vice President and Director of Statistics and Data Science, has been appointed to the External Advisory Board for North Carolina State…
-
RSV Antibody Provides Strong Infant Protection
August 26, 2025
New research has been published evaluating the effectiveness of nirsevimab, a long-acting monoclonal antibody recommended by the Centers for Disease Control and Prevention (CDC) in…
-
Applying Infectious Disease Research Infrastructure to Chronic Disease Prevention
June 11, 2025
Westat has coordinated a nationwide virtual research network of healthcare systems and research organizations that delivers relevant patient data to support research on respiratory disease…
-
Rebecca Birch
Principal Research Associate
-
Why Are People Reluctant to Share Health App Data?
May 5, 2025
In an age where smart watches track our heart rate, apps detect our sleep patterns, and digital platforms monitor the calories we burn, the potential…
-
Fine-Tuning LLMs to Improve Adverse Drug Event Detection and Reporting
April 7, 2025
The expedient, accurate detection of the severity of adverse drug events (ADEs) remains a serious challenge. Despite technological advancements, data-driven models often fail to precisely…
